Bioprocessing - Upstream & Downstream

Welcome to our Special Series E-book on Advanced Medicine!

Manufacturers must look to ease the headaches associated with the manufacture of mRNA-based products.

Biopharmaceutical development is in need of a speed boost. Multi-omics could be the answer.

Is autologous cell therapy a realistic proposition for solid tumors?

In the 20th century, physics and chemistry reshaped the world. Here’s why biology will be the game-changer in the 21st century.

What are the challenges and best practices in quality control for difficult-to-inspect products?

How can we maximize the potential and production of potentially life-saving therapies?

Lonza and Cytena combine expertise to allow biotherapeutic manufacturers to benefit from the advantages of Pichia pastoris as an expression system.

Edd Stone of TTP explains how the industry is overcoming the manufacturing challenges associated with cell therapies.

What role can regulators play in overcoming the barriers to the adoption of continuous manufacturing processes?